Skip to Content

'
William F. Benedict, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit 0018-5
Houston, TX 77030
Room Number: T7.3895
Email: wbenedic@mdanderson.org

Education & Training

Degree-Granting Education

1968 Albany Medical School, Albany, NY, MD, Medicine
1964 Drew University, Madison, NJ, BS, Zoology

Postgraduate Training

1969-1970 Clinical Residency, Albany Medical College, Albany, NY
1968-1969 Clinical Internship, Childrens Hospital of Los Angeles, Los Angeles, CA

Board Certifications

1/1968 California State Board of Medical Examiners

Experience/Service

Academic Appointments

Professor, Department of Molecular Hematology and Therapy, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, 1/1997-1/1998
Professor, Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 1/1995-1/1997
Professor, Baylor College of Medicine, Houston, TX, 1/1993-1/1995
Research Professor, Department of Hematology, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX, 1/1992-1/1995
Professor, Center for Biotechnology, Baylor College of Medicine, Houston, TX, 1/1988-1/1995
Professor, Opthalmology and Pediatrics, USC School of Medicine, Los Angeles, CA, 1/1986-1/1988
Professor, Pediatrics, Children's Hospital of Los Angeles, USC School of Medicine, Los Angeles, CA, 1/1983-1/1986
Associate Professor, Pediatrics, Children's Hospital of Los Angeles, USC School of Medicine, Los Angeles, CA, 1/1977-1/1983
Staff Physican, Pediatrics, Divisions of Hematology-Oncology and Medical Genetics, Children's Hospital of Los Angeles, Los Angeles, CA, 1/1973-1/1986
Assistant Professor, Pediatrics, Children's Hospital of Los Angeles, USC School of Medicine, Los Angeles, CA, 1/1973-1/1977

Administrative Appointments/Responsibilities

Director,Clayton Cancer Research Program, Center for Biotechnology, Baylor College of Medicine, The Woodlands, TX, 1/1988-1/1991
Director,Clayton Molecular Biology Program, Children's Hospital of Los Angeles, Los Angeles, CA, 1/1983-1/1988
Program Director,USC Training Grant in Viral and Chemical Carcinogenesis, USC School of Medicine, Los Angeles, CA, 1/1980-1/1988
Co-Director,Clayton Oncology Center, Children's Hospital of Los Angeles, Los Angeles, CA, 1/1978-1/1988
Head, Section of Chemical Carcinogenesis, Division of Hematology-Oncology, Children's Hospital of Los Angeles, Los Angeles, CA, 1/1977-1/1986

Institutional Committee Activities

member, Faculty Senate Transparancy and Communication Committee, 9/2012-present
member, Faculty Senate Academic Planning Committee, 9/2007-present
member, Faculty Senate, 9/2006-present
member, Faculty Senate Research Affairs Committee, 9/2006-present
Co-Director, Bladder SPORE Developmental Program, 1/2005-present
Director, Bladder SPORE Career Development, 1/2001-present
member, Executive Committee of Bladder SPORE, 1/2001-present
Executive Committee, Urology Training Program, 1/2000-present

Honors and Awards

2008 Emil Frei III Award for Excellence in Translational Research, UT MD Anderson Cancer Center
2007 Marcus Foundation Award, Marcus Foundation
2004 XXVllth Myron Karon Memorial Lecturership, Childrens Hospital of Los Angeles
2003 National Cancer Institute Award for the Outstanding Preclinical Poster, NCI
1995 Brochstein Award for Outstanding Achievement, Retina Research Foundation
1994 Theobald Smith Award, Albany Medical College
1990 Marjorie W. Margolin Prize, Retina Research Foundation
1989 22nd Congressional District, Certificate of Appreciation, U.S. Congress
1988 USC Associates Award for Creativity in Research and Scholarship, University of Southern California
1987 Mike Hogg Award, The University of Texas System Cancer Center and the M.D. Anderson Hospital and Tumor Institute
1986 Board of Scientific Counselors, Division of Cancer Etiology, National Cancer Institute
1986 General Motors Cancer Research Foundation Professor, University of Wisconsin Medical School
1986 Visiting Professor of the Year, Clinical Oncology Society of Australia
1974 Research Career Development Award, NCI

Selected Publications

Peer-Reviewed Original Research Articles

1. Benedict WF, Fisher M, Zhang XQ, Yang Z, Munsell MF, Dinney CN. Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study. Cancer Gene Ther 21(3):91-4, 3/2014. e-Pub 2/7/2014. PMCID: PMC3962717.
2. Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF. Phase I Trial of Intravesical Recombinant Adenovirus-Mediated Interferon-α2b Formulated in Syn3 for BCG failures in Non-Muscle-Invasive Bladder Cancer. J Urol 190(3):850-6, 9/2013. e-Pub 3/15/2013. PMID: 23507396.
3. Majewski T, Spiess PE, Bondaruk J, Black P, Clarke C, Benedict W, Dinney CP, Grossman HB, Tang KS, Czerniak B. Detection of bladder cancer using proteomic profiling of urine sediments. PLoS One 7(8):e42452, 2012. e-Pub 8/2012. PMCID: PMC3411788.
4. Zhibo Y, Zhang XQ, Dinney CNP, Benedict WF. Direct cytotoxicity produced by adenoviral-mediated interferon a infection in interferon resistant cancer cells Involves ER stress and caspase 4 activation. Cancer Gene Therapy. Cancer Gene Therapy 18(9):609-616, 9/2011. PMID: 21681220.
5. Zhang XQ, Yang Z, Benedict WF. Direct gene transfer of adenoviral-mediated interferon α into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related cytotoxicity. Cancer Gene Therapy 18(4):260-264, 4/2011. PMCID: PMCPMC3970572.
6. Zhang XQ, Dunner K, Benedict WF. Autophagy is induced by adenoviral-mediated interferon alpha treatment in interferon resistant bladder cancer and normal urothelial cells as a cell death protective mechanism but not by the bystander factors produced. Cancer Gene Ther 17(8):579-84, 8/2010. e-Pub 5/2010. PMCID: PMC2906639.
7. Fisher MB, Zhang XQ, McConkey DJ, Benedict WF. Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker. Cancer Gene Ther 16(7):567-572, 7/2009. e-Pub 2/2009. PMCID: PMC3891523.
8. Zhou J, Zhang XQ, Ashoori F, McConkey DJ, Knowles MA, Dong L, Benedict WF. Early RB94-produced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation. Cancer Gene Ther 16(1):13-19, 1/2009. e-Pub 7/2008. PMCID: PMCPMC3090001.
9. Zhang X, Dong L, Chapman E, Benedict WF. Conditioned medium from Ad-IFN-alpha-infected bladder cancer and normal urothelial cells is cytotoxic to cancer cells but not normal cells: further evidence for a strong bystander effect. Cancer Gene Ther 15(12):817-822, 12/2008. e-Pub 7/2008. PMID: 18617914.
10. Majewski T, Lee S, Jeong J, Yoon DS, Kram A, Kim MS, Tuziak T, Bondaruk J, Lee S, Park WS, Tang KS, Chung W, Shen L, Ahmed SS, Johnston DA, Grossman HB, Dinney CP, Zhou JH, Harris RA, Snyder C, Filipek S, Narod SA, Watson P, Lynch HT, Gazdar A, Bar-Eli M, Wu XF, McConkey DJ, Baggerly K, Issa JP, Benedict WF, Scherer SE, Czerniak B. Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest 88(7):694-721, 7/2008. e-Pub 5/2008. PMID: 18458673.
11. Pirollo KF, Rait A, Zhou Q, Zhang XQ, Zhou J, Kim CS, Benedict WF, Chang EH. Tumor-targeting nanocomplex delivery of tumor suppressor RB94 enhances chemosensitization of bladder carcinoma cells in vitro and in vivo. Clin Cancer Res 14(7):2190-2198, 4/2008. PMID: 18381961.
12. Lee S, Jeong J, Majewski T, Scherer SE, Kim MS, Tuziak T, Tang KS, Baggerly K, Grossman HB, Zhou JH, Shen L, Bondaruk J, Ahmed SS, Samanta S, Spiess P, Wu X, Filipek S, McConkey D, Bar-Eli M, Issa JP, Benedict WF, Czerniak B. Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci U S A 104(34):13732-37, 8/2007.
13. Zhang X, Yang Z, Dong L, Papageorgiou A, McConkey DJ, Benedict WF. Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects. Cancer Gene Ther 14(3):241-50, 3/2007. PMID: 17096027.
14. Sterman DH, Recio A, Carroll RG, Haas A, Gillespie CT, Vachani A, Kapoor V, Sun J, Hodinka R, Brown J, Corbley M, Parr M, Ho M, Pastan I, Machuzak M, Benedict WF, Zhang X, Lord EM, Litzky LA, Heitjan D, Vonderheide R, June C, Kaiser LR, Albelda SM. A phase I clinical trial of single-dose intrapleural interferon-beta gene transfer For malignant mesothelioma and metastatic pleural effusions: high rate of anti-tumor immune responses. Clin Cancer Res 13(15):4456-4466, 2007. PMID: 17671130.
15. Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, Dinney CP. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol 177(5):241-250, 2007. PMID: 17437845.
16. Zhang, X, Yang, Z,Dong, L, Papageorgiou, A, McConkey, D, Benedict, WF. Adenoviral-mediated alpha interferon overcomes resistance to interferon protein and has strong bystander effects. Cancer Gene Therapy 14/3:241-250, 2007. PMID: 17096027.
17. Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 5:3032-41, 12/2006. PMID: 17172406.
18. Sabichi A, Keyhani A, Tanaka N, Delacerda J, Lee IL, Zou C, Zhou JH, Benedict WF, Grossman HB. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. J Urol 175(3 Pt 1):1133-7, 3/2006. PMID: 16469639.
19. Tao Z, Connor RJ, Ashoori F, Dinney CP, Munsell M, Philopena JA, Benedict WF. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther 13(2):125-130, 2/2006. PMID: 16082384.
20. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ. Intravesical Ad-IFN alpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 10:525-32, 9/2004. PMID: 15336652.
21. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22(6):1014-24, 3/2004. PMID: 14981102.
22. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF, Dinney CP. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 171(2 Pt 1):570-4, 2/2004. PMID: 14713761.
23. Papageorgiou, A, Lashinger L, Milllikan, R, Benedict, WF, Dinney, CP, McConkey, DJ. Autocrine TRAIL production mediates interferon-induced apoptosis in human bladder cancer cells. Cancer Res 64:8973-8979, 2004.
24. Shariat SF, Matsumoto K, Kim J, Ayala GE, Zhou JH, Jian W, Benedict WF, Lerner SP. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol 170(3):985-9, 9/2003. PMID: 12913755.
25. Tanaka M, Gee JR, De La Cerda J, Rosser CJ, Zhou JH, Benedict WF, Grossman HB. Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. J Urol 170(3):975-8, 9/2003. PMID: 12913753.
26. Sweeney P, Karashima T, Ishikura H, Wiehle S, Yamashita M, Benedict WF, Cristiano RJ, Dinney CP. Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model. Cancer Res 63(14):4017-20, 7/2003. PMID: 12874000.
27. Zhang X, Multani AS, Zhou JH, Shay JW, McConkey D, Dong L, Kim CS, Rosser CJ, Pathak S, Benedict WF. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res 63(4):760-5, 2/2003. PMID: 12591722.
28. Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, Maneval DC, Karashima T, Czerniak BA, Dinney CP, Benedict WF. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther 9(8):687-91, 8/2002. PMID: 12136430.
29. Zhou JH, Rosser CJ, Tanaka M, Yang M, Baranov E, Hoffman RM, Benedict WF. Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. Cancer Gene Ther 9(8):681-6, 8/2002. PMID: 12136429.
30. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 8(4):1258-70, 4/2002. PMID: 11948141.
31. Nguyen C, Liang G, Nguyen TT, Tsao-Wei D, Groshen S, Lubbert M, Zhou JH, Benedict WF, Jones PA. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 93(19):1465-72, 10/2001. PMID: 11584062.
32. Tokunaga H, Shariat SF, Green AE, Brown RM, Zhou JH, Benedict WF, Lerner SP. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys 51(1):16-22, 9/2001. PMID: 11516846.
33. Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, Benedict WF. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther 7(12):1575-80, 12/2000. PMID: 11228536.
34. Shinohara H, Zhou J, Yoshikawa K, Yazumi S, Ko K, Yamaoka Y, Mizukami T, Yoshida T, Akinaga S, Tamaoki T, Motoda H, Benedict WF, Takahashi R. Retinoblastoma protein-initiated cellular growth arrest overcomes the ability of cotransfected wild-type p53 to induce apoptosis. Br J Cancer 83(8):1039-46, 10/2000. PMID: 10993652.
35. Czerniak B, Li L, Chaturvedi V, Ro JY, Johnston DA, Hodges S, Benedict WF. Genetic modeling of human urinary bladder carcinogenesis. Genes Chromosomes Cancer 27(4):392-402, 4/2000. PMID: 10719370.
36. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 6(3):1190-7, 3/2000. PMID: 10741751.
37. El-Naggar AK, Lai S, Clayman GL, Zhou JH, Tucker SA, Myers J, Luna MA, Benedict WF. Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol 30(9):1013-8, 9/1999. PMID: 10492034.
38. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285(5425):245-8, 7/1999. PMID: 10398599.
39. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 18(5):1197-203, 2/1999. PMID: 10022125.
40. Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WF, Batsakis JG. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18(5):1185-96, 2/1999. PMID: 10022124.
41. Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clin Cancer Res 4(8):1955-63, 8/1998. PMID: 9717825.
42. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4(4):829-34, 4/1998. PMID: 9563875.
43. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG, Benedict WF. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58(6):1090-4, 3/1998. PMID: 9515785.
44. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57(7):1217-21, 4/1997. PMID: 9102201.
45. Xu HJ, Zhou Y, Seigne J, Perng GS, Mixon M, Zhang C, Li J, Benedict WF, Hu SX. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 56(10):2245-9, 5/1996. PMID: 8625292.
46. Xu HJ, Xu K, Zhou Y, Li J, Benedict WF, Hu SX. Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. Proc Natl Acad Sci U S A 91(21):9837-41, 10/1994. PMID: 7937901.
47. Kornblau SM, Xu HJ, Zhang W, Hu SX, Beran M, Smith TL, Hester J, Estey E, Benedict WF, Deisseroth AB. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood 84(1):256-61, 7/1994. PMID: 8018920.
48. Zhou Y, Li J, Xu K, Hu SX, Benedict WF, Xu HJ. Further characterization of retinoblastoma gene-mediated cell growth and tumor suppression in human cancer cells. Proc Natl Acad Sci U S A 91(10):4165-9, 5/1994. PMID: 8183886.
49. Xu HJ, Sumegi J, Hu SX, Banerjee A, Uzvolgyi E, Klein G, Benedict WF. Intraocular tumor formation of RB reconstituted retinoblastoma cells. Cancer Res 51(16):4481-5, 8/1991. PMID: 1868470.
50. Xu HJ, Hu SX, Benedict WF. Lack of nuclear RB protein staining in G0/middle G1 cells: correlation to changes in total RB protein level. Oncogene 6(7):1139-46, 7/1991. PMID: 1861863.
51. Fung YK, Murphree AL, T'Ang A, Qian J, Hinrichs SH, Benedict WF. Structural evidence for the authenticity of the human retinoblastoma gene. Science 236(4809):1657-61, 6/1987. PMID: 2885916.
52. Cavenee WK, Murphree AL, Shull MM, Benedict WF, Sparkes RS, Kock E, Nordenskjold M. Prediction of familial predisposition to retinoblastoma. N Engl J Med 314(19):1201-7, 5/1986. PMID: 3702916.
53. Benedict WF, Weissman BE, Mark C, Stanbridge EJ. Tumorigenicity of human HT1080 fibrosarcoma X normal fibroblast hybrids: chromosome dosage dependency. Cancer Res 44(8):3471-9, 8/1984. PMID: 6744274.
54. Lee WH, Murphree AL, Benedict WF. Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 309(5967):458-60, 5/1984. PMID: 6728001.
55. Murphree AL, Benedict WF. Retinoblastoma: clues to human oncogenesis. Science 223(4640):1028-33, 3/1984. PMID: 6320372.
56. Benedict WF, Banerjee A, Mark C, Murphree AL. Nonrandom chromosomal changes in untreated retinoblastomas. Cancer Genet Cytogenet 10(4):311-33, 12/1983. PMID: 6652613.
57. Busbee DL, Benedict WF. High-density lipoproteins decrease both binding of a polynuclear aromatic hydrocarbon carcinogen to DNA and carcinogen-initiated cell transformation. Mutat Res 111(3):429-39, 11/1983. PMID: 6316134.
58. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305(5937):779-84, 10/1983. PMID: 6633649.
59. Gomer CJ, Rucker N, Banerjee A, Benedict WF. Comparison of mutagenicity and induction of sister chromatid exchange in Chinese hamster cells exposed to hematoporphyrin derivative photoradiation, ionizing radiation, or ultraviolet radiation. Cancer Res 43(6):2622-7, 6/1983. PMID: 6850580.
60. Sparkes RS, Murphree AL, Lingua RW, Sparkes MC, Field LL, Funderburk SJ, Benedict WF. Gene for hereditary retinoblastoma assigned to human chromosome 13 by linkage to esterase D. Science 219(4587):971-3, 2/1983. PMID: 6823558.
61. Benedict WF, Murphree AL, Banerjee A, Spina CA, Sparkes MC, Sparkes RS. Patient with 13 chromosome deletion: evidence that the retinoblastoma gene is a recessive cancer gene. Science 219(4587):973-5, 2/1983. PMID: 6336308.
62. Benedict WF, Wheatley WL, Jones PA. Differences in anchorage-dependent growth and tumorigenicities between transformed C3H/10T 1/2 cells with morphologies that are or are not reverted to a normal phenotype by ascorbic acid. Cancer Res 42(3):1041-5, 3/1982. PMID: 7059969.
63. Gomer CJ, Rucker N, Mark C, Benedict WF, Murphree AL. Tissue distribution of 3H-hematoporphyrin derivative in athymic "nude" mice heterotransplanted with human retinoblastoma. Invest Ophthalmol Vis Sci 22(1):118-20, 1982. PMID: 7056618.
64. Siegel MM, Chung HS, Rucker N, Siegel SE, Seeger RC, Isaacs H, Jr, Benedict WF. In vitro and in vivo preclinical chemotherapy studies of human neuroblastoma. Cancer Treat Rep 64(8-9):975-9, 8/1980. PMID: 7448832.
65. Benedict WF, Wheatley WL, Jones PA. Inhibition of chemically induced morphological transformation and reversion of the transformed phenotype of ascorbic acid in C3H/10T 1/2 cells. Cancer Res 40(8 Pt 1):2796-801, 8/1980. PMID: 6248214.
66. Sparkes RS, Sparkes MC, Wilson MG, Towner JW, Benedict W, Murphree AL, Yunis JJ. Regional assignment of genes for human esterase D and retinoblastoma to chromosome band 13q14. Science 208(4447):1042-4, 5/1980. PMID: 7375916.
67. Benedict WF, Dawson JA, Banerjee A, Murphree AL. The nude mouse model for human retinoblastoma: a system for evaluation of retinoblastoma therapy. Med Pediatr Oncol 8(4):391-5, 1980. PMID: 6935497.
68. Benedict WF, Lingua RW, Doiron DR, Dawson JA, Murphree AL. Tumor regression of human retinoblastoma in the nude mouse following photoradiation therapy: a preliminary report. Med Pediatr Oncol 8(4):397-401, 1980. PMID: 7453671.
69. Danon YL, Epstein MB, Siegel MM, Rucker N, Myers CP, Norman A, Benedict WF, Seeger RC. Variability in DNA distributions of human neuroblastomas after cyclophosphamide. Cancer Treat Rep 64(12):1275-81, 1980. PMID: 7471116.
70. Jones PA, Baker MS, Bertram JS, Benedict WF. Cell cycle-specific oncogenic transformation of C3H/10T1/2 clone 8 mouse embryo cells by 1-beta-D-arabinofuranosylcytosine. Cancer Res 37(7 Pt 1):2214-7, 7/1977. PMID: 861946.
71. Benedict WF, Banerjee A, Gardner A, Jones PA. Induction of morphological transformation in mouse C3H/10T1/2 clone 8 cells and chromosomal damage in hamster A(T1)C1-3 cells by cancer chemotherapeutic agents. Cancer Res 37(7 Pt 1):2202-8, 7/1977. PMID: 67887.
72. Freeman AE, Lake RS, Igel HJ, Gernand L, Pezzutti MR, Malone JM, Mark C, Benedict WF. Heteroploid conversion of human skin cells by methylcholanthrene. Proc Natl Acad Sci U S A 74(6):2451-5, 6/1977. PMID: 267938.
73. Seeger RC, Rayner SA, Banerjee A, Chung H, Laug WE, Neustein HB, Benedict WF. Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res 37(5):1364-71, 5/1977. PMID: 856461.
74. Jones PA, Baker MS, Benedict WF. The effect of 1-beta-D-arabinofuranosylcytosine on cell viability, DNA synthesis, and chromatid breakage in synchronized hamster fibrosarcoma cells. Cancer Res 36(10):3789-97, 10/1976. PMID: 986242.
75. Jones PA, Laug WE, Gardner A, Nye CA, Fink LM, Benedict WF. In vitro correlates of transformation in C3H/10T1/2 clone 8 mouse cells. Cancer Res 36(8):2863-7, 8/1976. PMID: 1277196.
76. Benedict WF. Morphological transformations and chromosome aberrations produced by two hair dye components. Nature 260(5549):368-9, 3/1976. PMID: 1256582.
77. Laug WE, Jones PA, Nye CA, Benedict WF. The effect of cyclic AMP and prostaglandins on the fibrinolytic activity of mouse neuroblastoma cells. Biochem Biophys Res Commun 68(1):114-9, 1/1976. PMID: 174561.
78. Benedict WF, Khwaja TA. A new hamster fibrosarcoma model for in vitro/in vivo evaluation of cancer chemotherapeutic agents. Med Pediatr Oncol 2(3):271-8, 1976. PMID: 62275.
79. Jones PA, Benedict WF, Baker MS, Mondal S, Rapp U, Heidelberger C. Oncogenic transformation of C3H/10T1/2 clone 8 mouse embryo cells by halogenated pyrimidine nucleosides. Cancer Res 36(1):101-7, 1976. PMID: 129280.
80. Jones PA, Laug WE, Benedict WF. Fibrinolytic activity in a human fibrosarcoma cell line and evidence for the induction of plasminogen activator secretion during tumor formation. Cell 6(2):245-52, 10/1975. PMID: 1182804.
81. Kouri RE, Kurtz SA, Price PJ, Benedict WF. 1-beta-D-arabinofuranosylcytosine-induced malignant transformation of hamster and rat cells in culture. Cancer Res 35(9):2413-9, 9/1975. PMID: 1149043.
82. Benedict WF, Jones PA, Laug WE, Igel HJ, Freeman AE. Characterisation of human cells transformed in vitro by urethane. Nature 256(5515):322-4, 7/1975. PMID: 1143334.
83. Jones P, Benedict W, Strickland S, Reich E. Fibrin overlay methods for the detection of single transformed cells and colonies of transformed cells. Cell 5(3):323-9, 7/1975. PMID: 167984.
84. Benedict WF, Rucker N, Faust J, Kouri RE. Malignant transformation of mouse cells by cigarette smoke condensate. Cancer Res 35(3):857-60, 3/1975. PMID: 1078786.
85. Benedict WF, Rucker N, Karon M. 1-beta-D-arabinofuranosylcytosine-induced chromatid breakage: effect of inhibition of DNA synthesis. J Natl Cancer Inst 54(2):431-3, 2/1975. PMID: 1167597.
86. Benedict WF, Rucker N, Mark C, Kouri RE. Correlation between balance of specific chromosomes and expression of malignancy in hamster cells. J Natl Cancer Inst 54(1):157-62, 1975. PMID: 1113299.
87. Laug WE, Jones PA, Benedict WF. Relationship between fibrinolysis of cultured cells and malignancy. J Natl Cancer Inst 54(1):173-9, 1975. PMID: 123008.
88. Thompson EB, Benedict WF, Owens IS, Nebert DW. Aryl hydrocarcon hydroxylase and tyrosine aminotransferase activities in somatic-cell hybrids derived from hepatoma tissue culture HTC (rat) cells and 3T3 (mouse) benzo(a)pyrene-resistant cells. Biochem Biophys Res Commun 56(3):605-10, 2/1974. PMID: 4151190.
89. Benedict WF, Gielen JE, Owens IS, Niwa A, Bebert DW. Aryl hydrocarbon hydroxylase induction in mammalian liver cell culture. IV. Stimulation of the enzyme activity in established cell lines derived from rat or mouse hepatoma and from normal rat liver. Biochem Pharmacol 22(21):2766-9, 11/1973. PMID: 4357894.
90. Benedict WF, Paul B, Porter IH. Giemsa banding in an established line of human malignant meningioma. Humangenetik 18(2):185-7, 4/1973. PMID: 4578385.
91. Benedict WF, Considine N, Nebert DW. Genetic differences in aryl hydrocarbon hydroxylase induction and benzo(a)pyrene-produced tumorigenesis in the mouse. Mol Pharmacol 9(2):266-77, 3/1973. PMID: 4123113.
92. Karon M, Benedict WF, Rucker N. Mechanism of 1- -D-arabinofuranosylcytosine-induced cell lethality. Cancer Res 32(12):2612-5, 12/1972. PMID: 4674677.
93. Karon M, Benedict WF. Chromatid breakage: differential effect of inhibitors of DNA synthesis during G 2 phase. Science 178(56):62, 10/1972. PMID: 4116011.
94. Benedict WF, Nebert DW, Thompson EB. Expression of aryl hydrocarbon hydroxylase induction and suppression of tyrosine aminotransferase induction in somatic-cell hybrids. Proc Natl Acad Sci U S A 69(8):2179-83, 8/1972. PMID: 4403306.
95. Benedict WF, Paul B, Nebert DW. Expression of benz[a]anthracene-inducible aryl hydrocarbon hydroxylase activity in mouse-hamster and mouse-human somatic-cell hybrids. Biochem Biophys Res Commun 48(2):293-8, 7/1972. PMID: 5065063.
96. Benedict WF, Porter IH. The cytogenetic diagnosis of malignancy in effusions. Acta Cytol 16(4):304-6, 7/1972. PMID: 4556411.
97. Nebert DW, Benedict WF, Gielen JE, Oesch F, Daly JW. Aryl hydrocarbon hydroxylase, epoxide hydrase, and 7,12-dimethylbenz(a)anthracene-produced skin tumorigenesis in the mouse. Mol Pharmacol 8(3):374-9, 5/1972. PMID: 5040935.
98. Benedict WF, Gielen JE, Nebert DW. Polycyclic hydrocarbon-produced toxicity, transformation, and chromosomal aberrations as a function of aryl hydrocarbon hydroxylase activity in cell cultures. Int J Cancer 9(2):435-51, 3/1972. PMID: 5064941.
99. Benedict WF. Rapid production of numerical and structural abnormalities in hamster cells by transforming doses of polycyclic hydrocarbons. J. Natl. Cancer Inst. 49:585-590, 1972.
100. Benedict WF, Brown CD, Porter IH. Long acrocentric marker chromosomes in malignant effusions and solid tumors. N Y State J Med 71(9):952-5, 5/1971. PMID: 5280177.
101. Benedict WF, Karon M. Chromatid breakage: cytosine arabinoside-induced lesions inhibited by ultraviolet irradiation. Science 171(972):680-2, 2/1971. PMID: 5540308.
102. Benedict WF, Harris N, Karon M. Kinetics of 1-beta-D-arabinofuranosylcytosine-induced chromosome breaks. Cancer Res 30(10):2477-83, 10/1970. PMID: 5528922.
103. Benedict WF, Porter IH, Brown CD, Florentin RA. Cytogenetic diagnosis of malignancy in recurrent meningioma. Lancet 1(7654):971-3, 5/1970. PMID: 4191936.
104. Porter IH, Benedict WF, Brown CD, Paul B. Recent advances in molecular pathology: a review. Some aspects of chromosome changes in cancer. Exp Mol Pathol 11(3):340-67, 12/1969. PMID: 4983316.

Invited Articles

1. Harlow, PJ, Siegel, MM, Siegel, SE, Benedict, WF. Antitumor Activity of Chemotherapeutic Agents Alone or in Combination Using a Human Neuroblastoma Model System. Proc. Cancer Res. and Ther 12:319-326, 1980.
2. Danon, YL, Epstein, MB, Siegel, MM, Siegel, SE, Meyers, CP, Benedict, WF. Seeger, RC. Flow Microfluorometric Analysis of Human Neuroblastoma DNA Distributions. Proc. Cancer Res. and Ther 12:287-298, 1980.

Book Chapters

1. Benedict, WFand Murphree, AL. Chromosomal and Genetic Basis for Attempting to Clone the Retinoblastoma Susceptibility Gene(s) Located Within 13q14. In: Banbury Report 14: Recombinant DNA Applications to Human Disease. Cold Spring Harbor Laboratory, 135-140, 1983.
2. Benedict, WFand Murphree, AL. Chromosomal Studies on Direct Preparations of Primary Retinoblastoma: Implication for the Function of the Retinoblastoma Gene. In: Cancer: Etiology and Prevention. Elsevier Science Publishing Co., Inc., 43-45, 1983.
3. Gomer, CJ, Szirth, BC, Doiron, DR, Jester, JV, Linqua, RW, Mark, C, Benedict, WFand Murphree, AL. Preclinical Evaluation of Hematoporphyrin Photoradiation Therapy for the Treatment of Intraocular Tumors, A Preliminary Report . In: Porphorin Workshop. Plenum Press, 109-114, 1983.
4. Benedict, WF, Wheatley, WLand Jones, PA. The Use of Ascorbic Acid for Selection of Transformed Cells With Differences in Tumorigenicities and Anchorage Independent Growth: Implications for Chemoprevention, Modulation and Mediation of Cancer by Vitamins. Karger, Basel, 114-118, 1983.
5. Benedict, WFand Murphree, AL. The Use of Cells from Patients with Genetically Inherited and Characterized Susceptibility to Cancer for Transformation Studies. In: Human Carcinogenesis. Academic Press, 509-515, 1983.
6. Benedict, WFand Jones, PA. Inhibition of Transformation and Oncogenic Progression by Ascorbic Acid: A Possible Role in Chemo-prevention. In: 34th Annual Symposium on Fundamental Cancer Research, 351-356, 1982.
7. Murphree, AL, Gomer, CJ, Doiron, DRand Benedict, AF. Recent Developments in the Genetics and Treatment of Retinoblastoma. In: Genetic Eye Disorders. Alan Liss, Inc., 681-687, 1982.
8. Benedict, WF(Rapporteur), Chouroulinkov, I, Fischer, PB, Marquardt, H, Pienta, RJand Yamasaki, H. Transformation in Cell Culture, Long-Term and Short-Term Screening Assays for Carcinogens: Critical Appraisal. In: LARC Monographs, 185-199, 1980.
9. Nebert, DW, Benedict, WF,and Kouri, R. Aromatic Hydrocarbon-produced Tumorigenesis and the Genetic Differences in Aryl Hydrocarbon Induction. In: Chemical Carcinogenesis. Marcel Dekker, Inc., 271-288, 1975.
10. Karon, M, Momparler, Rand Benedict, WF. Relevance of Molecular Mechanism of Drug Action to Clinical Trials in Man: Combination Therapy Model Using ara-C and aza-C. In: 27th Annual Symposium on Fundamental Cancer Research, 329-339, 1975.
11. Benedict, WF, Harris, Nand Karon, M. Kinetics of 1-B-D-Arabino-furanosylcytosine-induced Chromosome Breaks, Experimental Control of Mitosis:. In: MSS Information Corporation, 44-60, 1972.

Letters to the Editor

1. Benedict, WF, Rosen, WC, Brown, CDand Porter, IH. Chromosomal Abberrations in an Ovarian Cystadenoma. Lancet 11:640, 1969.
2. Benedict, WF, Porter, IH, Brown, CDand Doyle, GJ. Chromosomes in Malignancy. Lancet 1:922, 1968.
3. Benedict, WF, Brown, CD and Porter, IH. Chromosomes in Effusions. Lancet 1:1146, 1967.

Grant & Contract Support

Title: Isolation of a Potent Cancer Specific Cytotoxic Factor(s) Produced by Ad-IFNa in Normal Urothelial Cells – A Potential New Cancer Therapeutic Agent
Funding Source: Mike Hogg Foundation Award
Role: Principal Investigator
Duration: 12/1/2012 - 11/30/2013
 
Title: SPORE Supplemental for Phase lB Ad-IFN trial
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Colin Dinney
Duration: 9/25/2009 - 2012

Last updated: 4/8/2014